SARS Coronavirus 2 (SARS-CoV-2) Reagents

SARS-CoV-2 (COVID-19, 2019-nCoV) research reagents - antibodies and recombinant proteins for all structural proteins for SARS-CoV-2 


COVID-19 is an acute respiratory disease caused by novel coronavirus SARS-CoV-2. On March 11, 2020, the World Health Organization (WHO) classified COVID-19 as a pandemic[i]. Learn more about ProSci products for other human pathogenic coronaviruses (CoV) strains SARS-CoV-2 and MERS-CoV.

The SARS-CoV-2 structure[iii] consists of the spike protein (S), a membrane glycoprotein (M), an envelope protein (E), a nucleocapsid protein (N), and an RNA genome as represented in the figure below.

SARS-CoV-2 Research

ProSci Incorporated offers SARS-CoV-2 antibodies, recombinant proteins, and other reagents related to cellular entry: ACE2 receptor, TMPRSS2, and furin. In addition, ProSci Inc. is continuously adding new SARS-CoV-2 reagents for the spike protein and its sub-regions: S1, S2, the nucleocapsid protein, membrane protein, and envelope protein.

ProSci offers a comprehensive array of SARS-CoV-2 antibodies including llama single-domain antibodies and recombinant proteins, and antibodies against viral proteins; spike, nucleocapsid, envelope, ORF, and NSP. These antibodies can be used for various applications: IHC, Flow Cytometry, ELISA, WB, and Lateral-Flow.

SARS-CoV-2 Proteome

Diagram of SARS-CoV-2 proteome

Select your target of interest

Below are targets ProSci offers antibodies and recombinant proteins against:

More Areas of SARS-CoV-2 Research

ProSci offers more areas of SARS-CoV-2 research such as antibodies and recombinant proteins against the SARS-CoV-2 spike protein variant (Alpha, Beta, Gamma), antibodies validated by COVID-19 patient tissues, and matched pair antibodies against the spike protein and nucleocapsid protein of SARS-CoV-2.

SARS-CoV-2 Variant Antibodies and Recombinant Proteins

The use of the ProSci Spike Antibody (Cat. No. 3525) has been cited in numerous publications in 2020 and 2021. Of great interest now, while ProSci offers antibodies and recombinant proteins representing the full SARS-CoV-2 proteome, and host factors, the company also has a catalog of spike S1 antibodies to variant SARS-CoV-2 B.1.1.7 (Alpha) to the P681H point mutation (Cat. No. 9359) – this residue is adjacent to the Furin cleavage site, required for viral cell entry.

COVID-19 Patient Sample Validated Antibodies

ProSci enhances research efforts globally to understand this virus and its health effects. We have validated antibodies to all four structural proteins and several non-structural SARS-CoV-2 proteins by IHC with COVID-19 positive patient tissue samples, showing that these antibodies can detect the
virus itself.

Matched Pair Antibodies

ProSci offers SARS-CoV-2 antibody pairs validated by sandwich ELISA. These matched pair antibodies include antibodies against Spike S1, Spike RBD, and Nucleocapsid proteins. Some of the antibodies have been validated with COVID-19 patient samples.

SARS-CoV-2-related Citations

ProSci is continuing to dedicate time and effort to the research of the SARS-CoV-2 virus responsible for the COVID-19 pandemic. Our antibodies have been cited in the journals such as Cell, Nature Microbiology, The Journal of Vaccum Science and Technology B, and many more. Check out how ProSci antibodies and recombinant proteins were used in these studies, and how they can benefit you for yours!


[i] World Health Organization "WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020"

[ii] Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. Published online January 29, 2020. S0140-6736(20)30251-8

[iii] Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.

[iv] Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al.   SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. S0092–8674(20)30229–4 Advance online publication.